Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024. According to the Complaint, the Company made false and misleading statements to the market. Humana downplayed the impact of pressures on its adjusted EPS caused by pent-up demand for medical procedures as coronavirus concerns abated. Contrary to the Company's statements, the result of this demand was higher costs and increased ...